Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Our ability to edit genomes lags behind our capacity to sequence them, but the growing
understanding of CRISPR biology and its application to genome, epigenome and …

Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby
restoring normal tissue function,–. The interaction of menin with lysine methyltransferase 2A …

Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

Epigenetic modifications, including posttranslational modifications of histones, are closely
linked to transcriptional regulation. Trimethylated H3 lysine 4 (H3K4me3) is one of the most …

Abstract Purpose of Review This review seeks to identify and describe novel genetic and
protein targets and their associated therapeutics currently being used or studied in the …

Summary Background Ziftomenib (KO-539) is an oral selective menin inhibitor with known
preclinical activity in menin-dependent acute myeloid leukaemia models. The primary …

Pediatric cancers are frequently driven by genomic alterations that result in aberrant
transcription factor activity. Here, we used functional genomic screens to identify multiple …

Monotherapy with Menin inhibitor (MI), eg, SNDX-5613, induces clinical remissions in
patients with relapsed/refractory AML harboring MLL1-r or mtNPM1, but most patients either …

Chromosomal translocations of the nucleoporin 98 (NUP98) gene are found in acute
myeloid leukemia (AML) patients leading to very poor outcomes. The oncogenic activity of …